Author

Anne‐Sophie Jimenez

Observed names: A. Jimenez-pailhes, A.S. Pailhes-Jimenez, Anne-Sophie Jimenez, Anne-Sophie Jimenez-Pailhes, Anne-Sophie Jimenez-Pailhès, Anne-Sophie Pailhes-Jimenez, Anne-sophie Jimenez, Anne-sophie Jimenez-pailhes, Pailhes-Jimenez, Anne-Sophie, anne-Sophie Jimenez-Pailhes

Institution: CelLBxHealth (United Kingdom)

Observed institutions: Université Paris-Sud, Centre National de la Recherche Scientifique, Institut Pasteur, Kagawa University, Université de Lille, Université Paris-Saclay, Institut Pasteur de Lille, Institut Gustave Roussy, Institut de Biologie de Lille, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, Galpharma Co., Ltd. (Japan), CelLBxHealth (United Kingdom)

ORCID: 0009-0006-4573-7884

Observed ORCID: 0009-0006-4573-7884

OpenAlex ID: A5089720456

Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells

2014 · Dhafer Mrizak, Nathalie Martin, et al. · JNCI Journal of the National Cancer Institute · 221

Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells

2010 · Claire Gourzones, Aurore Gelin, et al. · Virology Journal · 130

Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients - evidence of non-exosomal transport

2013 · Claire Gourzones, François-Régis Ferrand, et al. · Virology Journal · 53

Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response

2015 · Jessie Thalmensi, Elodie Pliquet, et al. · OncoImmunology · 43

Analytical performance of the FDA-cleared Parsortix® PC1 system

2023 · Amy Templeman, M. Craig Miller, et al. · Journal of Circulating Biomarkers · 38

Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival

2015 · Nikiforos-Ioannis Kapetanakis, Catherine Uzan, et al. · Oncotarget · 38

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

2014 · Mélanie Gressette, Benjamin Vérillaud, et al. · PLoS ONE · 38

Profiling of Epstein‐Barr virus‐encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

2012 · Claire Gourzones, Anne‐Sophie Jimenez, et al. · Cancer · 26

Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

2024 · Mariacristina Ciccioli, Kyukwang Kim, et al. · Journal of Experimental & Clinical Cancer Research · 24

Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic

2012 · Benjamin Vérillaud, Mélanie Gressette, et al. · Infectious Agents and Cancer · 24

A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses

2012 · Clément Barjon, Toshiro Niki, et al. · Infectious Agents and Cancer · 22

A DNA telomerase vaccine for canine cancer immunotherapy

2019 · Jessie Thalmensi, Elodie Pliquet, et al. · Oncotarget · 18

Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix® System

2024 · Gabrielle Wishart, Amy Templeman, et al. · Current Issues in Molecular Biology · 14

Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection

2021 · Mariacristina Ciccioli, Natalia Bravo-Santano, et al. · Cancer Research · 3

Abstract 3705: Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells using Parsortix® isolation and BioView imaging technologies

2024 · Mariacristina Ciccioli, Alex Young, et al. · Cancer Research · 2

Interrogating HER2 status in Circulating Tumor Cells isolated using the Parsortix® System from Metastatic Breast Cancer patients

2024 · A. Young, L. Vlietinck, et al. · European Journal of Cancer · 2

Abstract A046: Development of a scoring system to classify HER2 protein expression in circulating tumor cells through immunofluorescence following isolation using Parsortix® instruments

2024 · Alex Young, Laila Vlietinck, et al. · Clinical Cancer Research · 1

Abstract P1-05-35: Identification of Circulating Tumor Cells captured by the FDA Cleared Parsortix® PC1 System from the Peripheral Blood of Metastatic Breast Cancer Patients using Immunofluorescence and Cytopathological Evaluations

2023 · Mariacristina Ciccioli, Richard Moore, et al. · Cancer Research · 1

Abstract 599: Investigation of PD-L1 expression in circulating tumor cells isolated using the Parsortix system in metastatic lung and breast cancer patients

2021 · Mariacristina Ciccioli, Amy Davis, et al. · Cancer Research · 1

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct

2011 · Anne-Sophie Jimenez, Mélanie Gressette, et al. · BMC Biotechnology · 1

Biom-71. Unlocking the Potential of Liquid Biopsy in Glioblastoma: an Extensive Evaluation of Circulating Biomarkers

2025 · Mariacristina Ciccioli, Morgan Spode, et al. · Neuro-Oncology

Abstract 1981: Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells

2025 · Mariacristina Ciccioli, Alex Young, et al. · Cancer Research

Abstract A038: Investigating PD-L1 status in circulating tumor cells isolated from blood samples of lung cancer patients

2024 · Morgan Spode, Chloe Goodwin, et al. · Clinical Cancer Research

Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumor Cell Analysis

2024 · M. Ciccioli, D. Greaves, et al. · European Journal of Cancer

Abstract 1033: Evaluation of HER2 status in circulating tumor cells isolated using the Parsortix® system

2023 · Nerea Borreguero-Munoz, Alex Young, et al. · Cancer Research

Works count: 42

Citation count: 700

H-index: 13

I10-index: 13